(Q53112763)

English

Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma: a propensity score matching study.

scientific article published in April 2013

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/23324079

Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma: a propensity score matching study. (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/23324079

0 references

hepatocellular carcinoma

1 reference

based on heuristic

inferred from title

4

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/23324079

author name string

Wei Bai

1

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/23324079

Yong Ji Wang

2

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/23324079

Yan Zhao

3

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/23324079

Zhan Xin Yin

5

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/23324079

Chuang Ye He

6

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/23324079

Rui Jun Li

7

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/23324079

Kai Chun Wu

8

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/23324079

Jie Lai Xia

9

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/23324079

Dai Ming Fan

10

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/23324079

Guo Hong Han

11

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/23324079

publication date

1 April 2013

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/23324079

Journal of Digestive Diseases

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/23324079

14

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/23324079

4

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/23324079

181-190

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/23324079

Global cancer statistics in the year 2000.

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12038

21 January 2018

Hepatocellular carcinoma: epidemiology and molecular carcinogenesis

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12038

21 January 2018

Treatment modalities for hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12038

21 January 2018

Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12038

21 January 2018

Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12038

21 January 2018

Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12038

21 January 2018

Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12038

21 January 2018

Overall survival after transarterial lipiodol infusion chemotherapy with or without embolization for unresectable hepatocellular carcinoma: propensity score analysis

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12038

21 January 2018

Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival.

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12038

21 January 2018

Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12038

21 January 2018

Quantitative analysis using ELISA of vascular endothelial growth factor and basic fibroblast growth factor in human colorectal cancer, liver metastasis of colorectal cancer and hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12038

21 January 2018

Sorafenib in advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12038

21 January 2018

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12038

21 January 2018

Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12038

21 January 2018

Spreds, inhibitors of the Ras/ERK signal transduction, are dysregulated in human hepatocellular carcinoma and linked to the malignant phenotype of tumors

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12038

21 January 2018

High serum vascular endothelial growth factor levels predict poor prognosis after radiofrequency ablation of hepatocellular carcinoma: importance of tumor biomarker in ablative therapies

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12038

21 January 2018

Platelet-derived growth factor receptor-alpha: a novel therapeutic target in human hepatocellular cancer.

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12038

21 January 2018

Targeted therapies for hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12038

21 January 2018

Combined approach to hepatocellular carcinoma: a new treatment concept for nonresectable disease

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12038

21 January 2018

Management of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12038

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12038

21 January 2018

A critical appraisal of propensity-score matching in the medical literature between 1996 and 2003.

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12038

21 January 2018

Sorafenib: where do we go from here?

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12038

21 January 2018

Loco-regional treatment of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12038

21 January 2018

Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response.

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12038

21 January 2018

Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111%2F1751-2980.12038

21 January 2018

Identifiers

10.1111/1751-2980.12038

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/23324079

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/23324079

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53112763&oldid=1725081514"